BRIEF published on 02/20/2026 at 21:42, 24 days 21 hours ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 24 days 21 hours ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
BRIEF published on 02/19/2026 at 10:33, 26 days 8 hours ago Mirova crosses a threshold at MEDINCELL Euronext Paris Voting Rights Transfer Of Shares Mirova MEDICELL
BRIEF published on 12/09/2025 at 14:55, 3 months 8 days ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 3 months 8 days ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 3 months 8 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 4 months 6 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 4 months 6 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 4 months 12 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 4 months 12 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
Published on 03/17/2026 at 13:30, 5 hours 18 minutes ago Hillcrest Energy Technologies Confirms ZVS PCS1000 Prototype on Track for June 2026
Published on 03/17/2026 at 13:30, 5 hours 18 minutes ago Namibia Critical Metals Welcomes Toyota Tsusho as Strategic Partner in the Lofdal Heavy Rare Earths Project
Published on 03/17/2026 at 13:00, 5 hours 48 minutes ago Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland
Published on 03/17/2026 at 13:00, 5 hours 48 minutes ago High-Resolution Airborne Survey Completed at Music Valley HREE Project
Published on 03/17/2026 at 12:30, 6 hours 18 minutes ago Revival Gold Targets Underground Resource Growth With Drilling at Beartrack-Arnett Gold Project in Idaho
Published on 03/17/2026 at 17:58, 50 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/17/2026 at 15:30, 3 hours 18 minutes ago Original-Research: Desert Gold Ventures Inc. (von GBC AG): Buy
Published on 03/17/2026 at 15:19, 3 hours 29 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Published on 03/17/2026 at 07:00, 11 hours 48 minutes ago Invitation to the Extraordinary General Meeting of shareholders
Published on 03/16/2026 at 18:00, 1 day ago Disclosure of trading in own shares from 09/03/2026 to 13/03/2026
Published on 03/16/2026 at 17:56, 1 day ago Reporting on share buyback transactions carried out between March 9 and March 13, 2026
